Pendal Group’s AbCellera Biologics ABCL Stock Holding History

Pendal Group’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-64,826	Closed	-$1.3M	–	537
2021 Q3	$1.3M	Buy	+64,826	New	+$1.15M	0.01%	292

Other funds holding ABCL

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

DCVC Bio Palo Alto, California $313K AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return

FFVM

Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Pendal Group's ABCL Position: Q4 2021 in Review

Pendal Group sold out of AbCellera Biologics (ABCL) in Q4 2021, closing a stake of 64,826 shares — an estimated $1.3M sold.

Pendal Group first reported a position in ABCL in Q3 2021 and held it in 1 quarter. The position peaked at $1.3M in Q3 2021. 124 funds tracked by Wall St. Rank hold ABCL as of Q4 2021.

Pendal Group reported no remaining AbCellera Biologics position as of Q4 2021 after selling out during the quarter.
Pendal Group sold 64,826 AbCellera Biologics shares in Q4 2021, an estimated $1.3M.
Pendal Group first reported a position in AbCellera Biologics in Q3 2021 and held it in 1 quarter.
Pendal Group's AbCellera Biologics position peaked at $1.3M in Q3 2021.
124 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2021.

Based on Pendal Group's 13F filing for Q4 2021, filed 18 Jan 2022.